Managing Seasonal Influenza: Oseltamivir Treatment Policy in Indonesia?
Abstract: To manage cases of
avian influenza A/H5N1 virus infection and in anticipation of a pandemic
triggered by this virus, Indonesia purchased and distributed oseltamivir to the
government health facilities. Oseltamivir is an antiviral drug that was
developed for the treatment of influenza infections. Disease surveillance and
research suggests that seasonal influenza (A/H1N1, A/H3N2 or B) results in
considerable morbidity and mortality in Indonesia, where over 15% of influenza-like
illness and severe acute respiratory illness patients test positive for the
influenza virus. Indonesia currently limits oseltamivir for the management of
avian influenza A/ H5N1cases and in anticipation of a pandemic triggered by the
A/H5N1 virus. We present the evidence for the use of oseltamivir in the
treatment of seasonal influenza infections so that doctors have the option to
prescribe the drug. We propose that the benefits of this approach will largely
outweigh the risk of antiviral resistance. We recommend that oseltamivir be
available for administration to patients with seasonal influenza infections
especially for those hospitalized and for groups with high risk of
complications and adverse outcomes. Overall, this will reduce morbidity and mortality
of seasonal influenza.
Key words: antiviral, policy, Indonesia,
influenza, treatment
Author: Herman Kosasih, Arie
Bratasena, Krisna Pangesti, Kanti Laras, Gina Samaan
Journal Code: jpkedokterangg140302
